omniture
logo
Search
Arbele Limited
Media Room

Latest News

rss

Arbele Announces Strategic Collaborations on AI Precision Oncology and Manufacturing to Advance CDH17-Targeted Immunotherapeutics

SEATTLE, Oct. 9, 2024 /PRNewswire/ -- Arbele, a leading innovator in biopharmaceutical & biotechnol...

2024-10-09 23:00 1265

Novel T-cell engager, CDH17 X CD3 cabotamig (ARB202) continues to explore dosing in patients with advanced gastrointestinal cancers

* The second DMC review recommends the continuation of dose escalation in the clinical trial as p...

2024-04-26 21:00 1567

Arbele announces early safety data for novel CDH17xCD3 bispecific T-cell engager at American Society of Clinical Oncology Breakthrough Meeting

SYDNEY, Aug. 2, 2023 /PRNewswire/ -- Arbele, a clinical-stage biotechnology company developing nove...

2023-08-03 07:00 1291

Arbele celebrates its 7th anniversary as a clinical-stage immunotherapy biotech and the opening of TibTech, its cancer diagnostics subsidiary

SEATTLE, May 5, 2023 /PRNewswire/ -- Arbele, a biotechnology company dedicated to fighting gastroin...

2023-05-05 15:00 1821

Arbele Announces Phase 1 First-in-Human Study of CDH17xCD3 Bispecific T-Cell Engager for Treatment of Gastrointestinal Cancers

SEATTLE, Aug. 10, 2022 /PRNewswire/ -- Arbele, a clinical stage biopharmaceutical company, announce...

2022-08-10 20:00 1754